Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.55 |
| ▸ | EGFR | P00533 | 8/20 | 0.54 |
| ▸ | LCK | P06239 | 6/20 | 0.54 |
| ▸ | ITK | Q08881 | 5/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24458762 | 0.93 | BTK (0.58) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL24458422 | 0.90 | BTK (0.59) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL24458640 | 0.86 | BTK (0.60) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL24458743 | 0.84 | BTK (0.54) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL24459135 | 0.84 | BTK (0.58) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL24458431 | 0.84 | BTK (0.64) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL24458452 | 0.83 | BTK (0.55) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL24458881 | 0.83 | BTK (0.55) | BTKEGFRLCKITKKDR | |
| SCHEMBL24458788 | 0.83 | BTK (0.50) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL31523737 | 0.83 | BTK (0.50) | BTKEGFRLCKITKFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | BTK 7/4885EGFR 51/4885LCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.